Overall survival is comparable between percutaneous radiofrequency ablation and liver resection as first-line therapies for solitary 3-5 cm hepatocellular carcinoma.

• Tác giả: Chien-Hung Chen, Shih-Da Chung, Tsung-Hui Hu, Chao-Hung Hung, Kwong-Ming Kee, Wei-Feng Li, Chih-Yun Lin, Yueh-Wei Liu, Sheng-Nan Lu, Chih-Chi Wang, Jing-Houng Wang, Yi-Hao Yen, Chee-Chien Yong
• Ngôn ngữ: eng
• Ký hiệu phân loại: 383.143 Overland mail
• Thông tin xuất bản: Germany : Langenbeck's archives of surgery , 2025
• Bộ sưu tập: NCBI
• ID: 65886

Tóm tắt

 PURPOSE: Few studies have compared survival outcomes between liver resection (LR) and percutaneous radiofrequency ablation (RFA) for treating solitary 3-5 cm hepatocellular carcinoma (HCC). We aimed to clarify this issue. METHODS: Patients with Child-Pugh class A liver disease and a solitary HCC of 3-5 cm without macrovascular invasion or extrahepatic metastasis who underwent LR or percutaneous RFA between 2011 and 2021 were enrolled in this retrospective study
  310 patients underwent LR and 114 patients underwent percutaneous RFA. Propensity score matching (PSM) was used to balance baseline variables, including age, sex, alpha-fetoprotein level, and Model for End-Stage Liver Disease score, between the two groups. RESULTS: Before PSM, 5-year overall survival (OS) and recurrence-free survival (RFS) were significantly lower in the percutaneous RFA group than in the LR group (both p <
  0.001). After PSM, 5-year OS was comparable between the two modalities (p = 0.367)
  however, 5-year RFS was significantly lower in the RFA group than in the LR group (p = 0.001). The two modalities did not differ in severe post-treatment complications (p = 1.000). CONCLUSIONS: Five-year OS did not differ between treatment modalities for patients with a solitary HCC of 3-5 cm
  however, the LR group's 5-year RFS was superior. LR should be recommended as the first-line treatment for these patients.